Medicines
SPC of 21/06/2021
AMOROLFINE ZYDUS 5%, medicated nail lacquer.
Composition
Amorolfine hydrochloride..........................................................................................................................6,400 g
Quantity corresponding to amorolfine base.............................................................................................5,000 g
For 100 ml.
Eudragit RL 100 (ammonio methacrylate copolymer type A), triacetin, n-butyl acetate, ethyl acetate, anhydrous ethanol.
Dosage and administration
Dosage
Apply AMOROLFINE ZYDUS to the affected nails at a dose of once or twice per week.
Method of administration
To apply the lacquer, carefully follow the recommendations below:
For packs without accessories:
a) Before the first application of AMOROLFINE ZYDUS, carefully clean the nails, and file the affected area of the nail (in particular the nail surface) with a nail file as completely as possible.
Take care not to file the periungual skin.
b) Clean the nail surface and degrease it using a compress or a cloth soaked in solvent.
c) Apply the lacquer using one of the reusable spatulas over the entire affected nail. Clean the reusable spatula between each nail to avoid contaminating the lacquer. Do not wipe the spatula on the rim of the bottle.
d) It is important to thoroughly clean the spatula using a compress or a cloth soaked in solvent after each application, before reusing it on another nail, to avoid contaminating the lacquer.
e) If lacquer has been deposited on the outside of the stopper during handling, it is important to clean it using a compress or a cloth soaked in solvent, to avoid applying this lacquer to the skin.
f) Reseal the bottle tightly.
Repeat all of the above steps for each affected nail.
Cosmetic nail lacquers may be applied at least 10 minutes after application of AMOROLFINE ZYDUS lacquer.
Treatment must be continued without interruption until complete regeneration of the nail and clinical and mycological cure of the affected areas.
The duration of treatment is generally 6 months for fingernails and 9 months for toenails (it depends essentially on the severity and location of the infection and the extent of nail involvement).
Special instructions:
- Do not reuse nail files on healthy nails.
- Before each new application, file the affected nails if necessary and in all cases clean them with nail polish remover to remove residual varnish.
- When handling organic solvents (white spirit, thinners…), it is necessary to wear waterproof gloves to protect the AMOROLFINE ZYDUS nail varnish layer on the nails.
For packs with accessories:
a) Before the first application of AMOROLFINE ZYDUS, carefully clean the nails, and file the affected area of the nail (in particular the nail surface) with a nail file as completely as possible.
Take care not to file the periungual skin.
b) Clean the nail surface and degrease it using one of the cleansing wipes provided, to remove any trace of residual varnish.
c) Apply the lacquer using one of the reusable spatulas over the entire affected nail. Clean the reusable spatula between each nail to avoid contaminating the lacquer. Do not wipe the spatula on the rim of the bottle.
d) It is important to thoroughly clean the spatula using one of the cleansing wipes provided after each application, before reusing it on another nail, to avoid contaminating the varnish.
e) If varnish has been deposited on the outside of the cap during handling, it is important to clean it using one of the cleansing wipes provided, to avoid applying this varnish to the skin.
f) Reseal the bottle tightly.
Repeat all of the above steps for each affected nail.
Cosmetic nail lacquers may be applied at least 10 minutes after application of AMOROLFINE ZYDUS lacquer.
Treatment must be continued without interruption until complete regeneration of the nail and clinical and mycological cure of the affected areas.
The duration of treatment is generally 6 months for fingernails and 9 months for toenails (it depends essentially on the severity and location of the infection and the extent of nail involvement).
Special instructions:
- Do not reuse nail files on healthy nails.
- Before each new application, file the affected nails if necessary and in all cases clean them with the cleansing wipes to remove residual varnish.
- When handling organic solvents (white spirit, thinners…), it is necessary to wear waterproof gloves to protect the AMOROLFINE ZYDUS nail varnish layer on the nails.
Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section Composition.
Warnings and precautions
Special warnings:
Avoid any contact of AMOROLFINE ZYDUS with the eyes, ears or mucous membranes.
AMOROLFINE ZYDUS should be used with caution in patients with conditions predisposing to nail disorders (peripheral circulatory disorders, diabetes, immune system diseases) as well as in patients presenting with nail dystrophy or severely damaged nails (more than two-thirds of the nail plate is affected). In these cases a systemic treatment should be considered.
Do not use artificial nails during treatment with AMOROLFINE ZYDUS.
If organic solvents are handled, waterproof gloves must be worn, otherwise the varnish will be dissolved.
After applying AMOROLFINE ZYDUS nail lacquer, a period of at least 10 minutes must be observed before applying a cosmetic nail varnish. Before repeating the application of AMOROLFINE ZYDUS nail lacquer, the cosmetic nail varnish must be carefully removed.
A systemic or local allergic reaction could possibly occur after use of this medicine. If this occurs, the medicine must be stopped immediately and a doctor must be consulted. Carefully remove the product using nail polish remover. The medicine must not be reused.
Precautions for use
In the absence of data, the use of AMOROLFINE ZYDUS is not recommended in patients aged less than 18 years.
Interactions
The data available to date do not suggest the existence of clinically significant interactions.
Fertility, pregnancy and breastfeeding
There are limited data on the use of amorolfine in pregnant and breastfeeding women. Only a small number of pregnancies exposed to topical amorolfine have been reported after marketing, so the potential risk is unknown.
Studies performed in animals have shown reproductive toxicity at high oral doses (see section Preclinical safety).
It is not known whether amorolfine is excreted in human milk.
AMOROLFINE ZYDUS should not be used during pregnancy and breastfeeding, except in cases of real necessity.
Adverse effects
|
System Organ Class |
Frequency |
Adverse effects |
|
Immune system disorders |
Frequency not known (cannot be estimated from the available data) |
Hypersensitivity (systemic allergic reaction)* |
|
Skin and subcutaneous tissue disorders |
Rare (≥1/10 000, <1/1 000) |
Nail disorder, nail discolouration, brittle nails (onychoclasis), fragile nails (onychorrhexis) |
|
Very rare (<1/10 000) |
Sensation of skin burning |
|
|
Frequency not known (cannot be estimated from the available data) |
Erythema, pruritus, contact dermatitis, urticaria, blister |
|
|
* Adverse effects reported since marketing. |
||
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reaction via the national reporting system: National Agency for the Safety of Medicines and Health Products (ANSM) and the network of Regional Centres of Pharmacovigilance - Website: www.signalement-sante.gouv.fr.
Overdose
No systemic signs of overdose are expected after topical application of AMOROLFINE ZYDUS.
In case of accidental ingestion, appropriate symptomatic measures should be taken.
Pharmacodynamics
Pharmacotherapeutic class: OTHER ANTIFUNGALS FOR TOPICAL USE, ATC code: D01AE16.
AMOROLFINE ZYDUS is a topical antifungal. The active ingredient, amorolfine, derived from morpholine, belongs to a new chemical class of antifungals.
Its fungistatic and fungicidal effect is based on an alteration of the fungal cell membrane mainly targeting sterol biosynthesis.
The ergosterol content is reduced. An accumulation of atypical sterols leads to morphological changes in cell membranes and organelles that cause the death of the fungal cell.
Amorolfine has a broad antimycotic spectrum. It is very effective against the usual or occasional agents of onychomycosis:
- The yeasts:
- Candida albicans and other Candida species,
- The dermatophytes:
- Trichophyton rubrum, Trichophyton interdigitale and Trichophyton mentagrophytes, other species of Trichophyton,
- Epidermophyton floccosum,
- Microsporum.
- Moulds:
- Scopulariopsis.
- The dematiaceae (black fungi):
- Hendersonula, Alternaria, Cladosporium.
- Species with low sensitivity:
- Aspergillus, Fusarium, mucorales.
Pharmacokinetics
Amorolfine in the form of a nail lacquer penetrates and diffuses through the nail plate and is able to eradicate fungi that are poorly accessible in the nail bed.
The general absorption of the active ingredient is negligible, with the plasma concentration remaining below the sensitivity threshold, even after one year of use.
Preclinical safety
In rats, amorolfine is not teratogenic and is not embryotoxic at the maximum oral dose tested of 40 and 80 mg/kg/day. However, signs of maternal toxicity (weight loss) were observed at doses of 40 and 80 mg/kg/day.
In rabbits, amorolfine is not teratogenic but has an embryotoxic effect at the maximum oral dose tested of 10 mg/kg/day. Maternal weight loss, reflecting maternal toxicity, was also observed at the dose of 10 mg/kg/day.
Due to the very low systemic absorption of amorolfine following application to the nail or skin, the potential risk of toxicity to the human fetus is negligible.
Prescription, supply and reimbursement
| Marketing authorisation (AMM) |
|
| Price: |
|
Collection.
ZAC DES HAUTES PATURES 25 RUE DES PEUPLIERS - BÂT. L
92752 NANTERRE CEDEX
Tel: 01 41 19 18 50 https://www.zydusfrance.com/
Source: VIDAL · Updated on 10/11/2026. This information does not replace advice from a healthcare professional.
